Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

Summary

OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS). II. Determine the side-effects and benefits associated with DAP.

Timeline

Start

1994-08

Primary completion

—

Completion

1998-06

Drugs

Indications